Copd Equities

Pharmaceuticals
Sanofi's Dupixent Emerges as First Biologic Treatment for COPD in China, Pioneering a New Era in Respiratory Medicine Sep 28, 2024
Pharmaceuticals
Dupixent® (dupilumab) Becomes China's First Biologic for COPD through Regeneron Pharmaceuticals Sep 28, 2024
Pharmaceuticals
Sanofi's Dupixent Secures EU Approval as Novel COPD Therapy Jul 4, 2024
Pharmaceuticals
Amgen and AstraZeneca Showcase Efficacy of Tezspire in Treating COPD Across Diverse Patients May 21, 2024